Alluvi, known as BI 4744, represents a notable advance in obesity therapy. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates impressive efficacy in clinical https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/